Clinical trials: Olaparib
- Drug or intervention Olaparib
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual…
- Trial name
- NCT04889404
- Where
- 60 sites in Japan
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Endometrial Cancer
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the…
- Trial name
- NCT06995833
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Breast Cancer
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual…
- Trial name
- NCT05677308
- Where
- 38 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Solid Tumours
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.
- Trial name
- NCT04236414
- Testing
- Olaparib
- Where
- 10 sites in Denmark, France and 4 more
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
[Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in actual clinical use. 1. ADR development in actual clinical use 2. Factors which may affect safety and efficacy 3.
- Trial name
- NCT03505307
- Volunteers
- 846 people
- Sponsor
- AstraZeneca
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca